financetom
Business
financetom
/
Business
/
Coca-Cola Rides Zero Sugar Boom, Diet Coke Uptick To Solid Q3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coca-Cola Rides Zero Sugar Boom, Diet Coke Uptick To Solid Q3
Oct 21, 2025 7:41 AM

Coca-Cola Company ( KO ) shares are trading higher in the premarket session on Tuesday following the company’s report of third-quarter results.

The food and beverage giant reported third-quarter adjusted earnings per share of 82 cents, beating the analyst consensus estimate of 78 cents.

Quarterly sales of $12.5 billion (+5% year over year) outpaced the Street view of $12.394 billion. Organic revenues (non-GAAP) grew 6%.

Price/mix grew 6%, primarily driven by pricing actions in the marketplace and a favorable mix.

Also Read: Why Coca-Cola Just Sold Most Of Its Africa Bottling Empire

Quarterly Metrics

Coca-Cola’s third-quarter operating margin expanded to 32% from 21.2% a year ago. On an adjusted basis, comparable operating margin rose to 31.9% from 30.7% in the prior year. Operating income grew 59%, which included items impacting comparability and a currency headwind.

Adjusted gross margin was 61%, lower than 61.2% in the year-ago period. Unit case volume grew 1%, primarily driven by growth in Central Asia, North Africa, Brazil, and the United Kingdom.

Diet Coke Up

Sparkling soft drinks were even year over year. Trademark Coca‑Cola grew 1%, driven by growth in Europe, the Middle East, Africa and Asia Pacific.

Coca‑Cola Zero Sugar grew 14%, driven by growth across all geographic operating segments. Diet Coke/Coca‑Cola Light grew 2%, primarily driven by growth in North America and Asia Pacific.

Sparkling flavors declined 1%, as growth in Europe, the Middle East and Africa was more than offset by a decline in Asia Pacific.

Juice, value-added dairy and plant-based beverages declined 3%, as growth in Latin America was more than offset by a decline in Asia Pacific.

Water, sports, coffee and tea grew 3%. Water grew 3%, driven by growth across all geographic operating segments.

Coca-Cola Africa Sale

Earlier on Tuesday, Coca-Cola and Gutsche Family Investments disclosed a deal to sell a 75% controlling stake in Coca-Cola Beverages Africa (CCBA) to Coca-Cola HBC AG for around $3.4 billion.

Under the deal, The Coca-Cola Company ( KO ) will sell 41.52% of its 66.52% ownership in CCBA, while Coca-Cola HBC will also purchase the 33.48% stake held by Gutsche Family Investments.

Notably, CCBA operates in 14 African countries and represents around 40% of all Coca-Cola product sales in the region.

The sale is expected to be completed by the end of 2026.

During its conference call, Coca-Cola stated that certain consumer segments are under pressure. The company cited inflationary pressures and trade dynamics among the key factors weighing on demand.

Outlook

Coca-Cola expects its fiscal year 2025 adjusted earnings per share to be $2.97. The company expects comparable EPS (non-GAAP) growth of approximately 3%, compared to $2.88 in 2024.

The company expects to generate free cash flow excluding the fairlife contingent consideration payment (non-GAAP) of at least $9.8 billion.

This consists of cash flow from operations excluding the fairlife contingent consideration payment of approximately $12.0 billion, less capital expenditures of roughly $2.2 billion (updated from $9.5 billion).

Coca-Cola stated that its fourth-quarter 2025 results are likely to experience a slight foreign exchange tailwind to comparable net revenue, but a 4% to 5% headwind to comparable earnings per share.

The company stated that for the full year 2026, it expects slight foreign exchange tailwinds to both comparable net revenue and comparable EPS growth, based on current rates and hedges.

Price Action: KO shares were trading higher by 2.73% to $70.32 premarket at last check on Tuesday.

Read Next:

Stock Market Today: S&P 500, Dow Jones, Nasdaq Futures Inch Lower— Netflix, Coca-Cola And RTX Corp In Focus

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Troilus Gold Says Sayona Mining Has Divested Its Entire Equity Position in Troilus
Troilus Gold Says Sayona Mining Has Divested Its Entire Equity Position in Troilus
Apr 22, 2024
07:51 AM EDT, 04/22/2024 (MT Newswires) -- Troilus Gold Corp. ( CHXMF ) reported Monday that Sayona Mining Ltd. has divested its entire equity position in Troilus. Last week, a statement noted, Sayona sold approximately 19.2 million Troilus shares at C$0.63, which was executed through a block trade facilitated by a Tier-1 Canadian brokerage firm. The statement said these shares...
Otis Worldwide Greenhouse Gas Reduction Targets Gain Science Based Targets Initiative's Approval
Otis Worldwide Greenhouse Gas Reduction Targets Gain Science Based Targets Initiative's Approval
Apr 22, 2024
07:47 AM EDT, 04/22/2024 (MT Newswires) -- Otis Worldwide ( OTIS ) said Monday the Science Based Targets initiative has approved its near-term greenhouse gas reduction targets. The approved targets include slashing scope 1 and 2 emissions by 55% by 2033 from a 2021 base and reducing scope 3 emissions by 33% over the same period. ...
Vista Outdoor urges MNC Capital to increase offer price on $3 bln bid
Vista Outdoor urges MNC Capital to increase offer price on $3 bln bid
Apr 22, 2024
April 22 (Reuters) - Vista Outdoor ( VSTO ) is engaging in discussions with investment firm MNC Capital for a better deal than its all-cash offer to acquire the company for $3 billion, the sporting and outdoor products maker said on Monday. Vista is already in talks to sell its sporting goods business to privately-held Czech defence and civil manufacturing...
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies
Apr 22, 2024
07:51 AM EDT, 04/22/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Monday it has signed a capacity reservation and supply agreement with integrated development and manufacturing organization Cellares to manufacture CAR T cell therapies. The pharmaceutical company said the deal is worth up to $380 million in upfront and milestone payments. Under the agreement, Cellares will target certain...
Copyright 2023-2026 - www.financetom.com All Rights Reserved